BridgeMD
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus
EU CTIS ID: 2023-506368-14-00
What this study is testing
Evaluate the long-term safety and tolerability of dapirolizumab pegol (DZP) treatment.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment - The participant completed one of the parent studies within 4 weeks prior to entry to this study
You likely can't join if
- - Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant’s ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study
The study team makes the final eligibility decision.
Where it's taking place
- Puerto Rico
- Colombia
- Serbia
- China
- Korea, Republic of
- Taiwan
- Philippines
- Mexico
- Japan
- United States
- Canada
- United Kingdom
- Chile
- Peru
- Argentina
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Puerto Rico; Colombia; Serbia; China; Korea, Republic of; Taiwan and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.